The Manufacturers Life Insurance Company bought a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 37,782 shares of the company’s stock, valued at approximately $888,000. The Manufacturers Life Insurance Company owned 0.09% of Spyre Therapeutics at the end of the most recent quarter.
Several other large investors also recently modified their holdings of SYRE. Amalgamated Bank acquired a new stake in Spyre Therapeutics during the 2nd quarter worth approximately $28,000. Quest Partners LLC acquired a new stake in shares of Spyre Therapeutics in the 2nd quarter valued at about $36,000. SG Americas Securities LLC bought a new stake in shares of Spyre Therapeutics in the second quarter valued at about $130,000. Carlyle Group Inc. acquired a new position in shares of Spyre Therapeutics during the second quarter worth about $227,000. Finally, Profund Advisors LLC acquired a new stake in Spyre Therapeutics in the 2nd quarter valued at approximately $296,000. 80.39% of the stock is currently owned by institutional investors.
Spyre Therapeutics Price Performance
Shares of Spyre Therapeutics stock opened at $28.70 on Monday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -0.40 and a beta of 2.92. The business has a fifty day simple moving average of $27.58 and a two-hundred day simple moving average of $30.62. Spyre Therapeutics, Inc. has a 1 year low of $8.43 and a 1 year high of $47.97.
Analysts Set New Price Targets
A number of research firms have recently issued reports on SYRE. Evercore ISI began coverage on shares of Spyre Therapeutics in a report on Tuesday, July 16th. They issued an “outperform” rating on the stock. Wedbush initiated coverage on shares of Spyre Therapeutics in a research note on Wednesday, September 4th. They set an “outperform” rating and a $45.00 price objective for the company. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $43.43.
View Our Latest Stock Analysis on Spyre Therapeutics
About Spyre Therapeutics
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Featured Stories
- Five stocks we like better than Spyre Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- About the Markup Calculator
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- What is the Shanghai Stock Exchange Composite Index?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report).
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.